CTD Holdings begins dosing in Phase I/II trial of Trappsol Cyclo to treat NPC

CTD Holdings has commenced patient dosing in a Phase I/II clinical trial of its intravenous drug candidate Trappsol Cyclo for the treatment of patients in Europe with Niemann-Pick disease type C (NPC).
Source: Drug Development Technology - Category: Pharmaceuticals Source Type: news